Earnings Analysis of Eclipse Resources Corporation(NYSE:ECR): aTyr Pharma, Inc.(NASDAQ:LIFE)

0
2

Eclipse Resources Corporation (ECR) will report its next earnings on Oct 31 AMC. The company reported the earnings of $0.04/Share in the last quarter where the estimated EPS by analysts was $-0.02/share. The difference between the expected and actual EPS was $0.06/share, which represents an Earnings surprise of 300%.

Many analysts are providing their Estimated Earnings analysis for Eclipse Resources Corporation and for the current quarter 10 analysts have projected that the stock could give an Average Earnings estimate of $0.03/share. These analysts have also projected a Low Estimate of $0/share and a High Estimate of $0.07/share.

In case of Revenue Estimates, 8 analysts have provided their consensus Average Revenue Estimates for Eclipse Resources Corporation as 145.5 Million. According to these analysts, the Low Revenue Estimate for Eclipse Resources Corporation is 129.5 Million and the High Revenue Estimate is 191.48 Million. The company had Year Ago Sales of 104.06 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for ECR to be 50%. They are projecting Next Quarter growth of 33.33%. For the next 5 years, Eclipse Resources Corporation is expecting Growth of 85.41% per annum, whereas in the past 5 years the growth was 700% per annum.

Some buy side analysts are also providing their Analysis on Eclipse Resources Corporation, where 2 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Eclipse Resources Corporation might touch $3.2 high while the Average Price Target and Low price Target is $2.39 and $1.25 respectively.

Eclipse Resources Corporation closed its last trading session at $1.11 with the gain of 0%. The Market Capitalization of the company stands at 341.82 Million. The Company has 52-week high of $2.79 and 52-week low of $0.99. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -6.88% where SMA50 and SMA200 are -8.45% and -23.16% respectively. The Company Touched its 52-Week High on 01/03/18 and 52-Week Low on 10/30/18.

The Relative Volume of the company is 0.58 and Average Volume (3 months) is 1.24 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 8.88.

The company shows its Return on Assets (ROA) value of -2.3%. The Return on Equity (ROE) value stands at -4.9%. While it’s Return on Investment (ROI) value is 1.2%.

While looking at the Stock’s Performance, Eclipse Resources Corporation currently shows a Weekly Performance of 0.91%, where Monthly Performance is -11.2%, Quarterly performance is -18.38%, 6 Months performance is -28.39% and yearly performance percentage is -54.51%. Year to Date performance value (YTD perf) value is -53.75%. The Stock currently has a Weekly Volatility of 7.39% and Monthly Volatility of 6.97%.

aTyr Pharma, Inc. (LIFE) will report its next earnings on Nov 13 AMC. The company reported the earnings of $-0.24/Share in the last quarter where the estimated EPS by analysts was $-0.31/share. The difference between the expected and actual EPS was $0.07/share, which represents an Earnings surprise of 22.6%.

Many analysts are providing their Estimated Earnings analysis for aTyr Pharma, Inc. and for the current quarter 4 analysts have projected that the stock could give an Average Earnings estimate of $-0.23/share. These analysts have also projected a Low Estimate of $-0.28/share and a High Estimate of $-0.19/share.

These analysts also forecasted Growth Estimates for the Current Quarter for LIFE to be 38.5%. They are projecting Next Quarter growth of 36.11%. For the next 5 years, aTyr Pharma, Inc. is expecting Growth of 18.22% per annum, whereas in the past 5 years the growth was 36.9% per annum.

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for aTyr Pharma, Inc. might touch $1.8 high while the Average Price Target and Low price Target is $1.18 and $0.75 respectively.

aTyr Pharma, Inc. closed its last trading session at $0.59 with the gain of 0%. The Market Capitalization of the company stands at 18.01 Million. The Company has 52-week high of $4.22 and 52-week low of $0.49. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 1.34% where SMA50 and SMA200 are -10.05% and -55.78% respectively. The Company Touched its 52-Week High on 01/17/18 and 52-Week Low on 11/15/18.

The Relative Volume of the company is 0.55 and Average Volume (3 months) is 452.81 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -53.6%. The Return on Equity (ROE) value stands at -78.1%. While it’s Return on Investment (ROI) value is 0%.

While looking at the Stock’s Performance, aTyr Pharma, Inc. currently shows a Weekly Performance of 1.83%, where Monthly Performance is -10.8%, Quarterly performance is -28.05%, 6 Months performance is -30.18% and yearly performance percentage is -84.87%. Year to Date performance value (YTD perf) value is -83.14%. The Stock currently has a Weekly Volatility of 11.42% and Monthly Volatility of 12.96%.

SHARE